Prothymosin-alpha and Ki-67 expression in pituitary adenomas

Wierzbicka-Tutka, Iga; Sokołowski, Grzegorz; Bałdys-Waligórska, Agata; Adamek, Dariusz; Radwańska, Edyta; Gołkowski, Filip

doi:10.5604/17322693.1223796

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Ki67 is a dependable indicator of cancer cellular duplication and migration ( 62 ). Studies have suggested that in diverse cancers, Ki67 activation usually concurs with upregulated CYTOR, low expression of miR-206 or promoted PTMA ( 63 - 65 ), which is consistent with the results of the present study. Based on the above, the CYTOR/miR-206/PTMA axis may be valuable in NSCLC research.…”

Section: Discussionsupporting

confidence: 93%

lncRNA cytoskeleton regulator reduces non‑small cell lung cancer radiosensitivity by downregulating miRNA‑206 and activating prothymosin α

Jiang

Yu²,

et al. 2021

Int J Oncol

View full text Add to dashboard Cite

The present study aimed to explore the role of the long noncoding RNA cytoskeleton regulator (CYTOR) in non-small cell lung cancer (NSCLC) radiosensitivity by manipulating the microRNA (miR)-206/prothymosin α (PTMA) axis. First, 58 pairs of NSCLC and paracancerous tissues, normal human lung epithelial cells and NSCLC cells were collected to analyze CYTOR expression and the relation- ship between CYTOR and NSCLC prognosis. Subsequently, CYTOR expression in radioresistant cells was assessed. Radioresistant cells with low CYTOR expression and parental cells with high CYTOR expression were established. Functional assays were then performed to assess changes in cell radiosensitivity after irradiation treatment. Subsequently, the downstream mechanism of CYTOR was explored. The binding interactions between CYTOR and miR-206 and between miR-206 and PTMA were predicted and certified. Xenograft transplantation was applied to confirm the role of CYTOR in the radiosensitivity of NSCLC. CYTOR was overexpressed in NSCLC and was associated with poor prognosis. CYTOR was further upregulated in NSCLC cells with radioresistance. CYTOR knockdown enhanced the radiosensitivity of NSCLC cells, while overexpression of CYTOR led to the opposite result. Mechanistically, CYTOR specifically bound to miR-206 and silencing CYTOR promoted miR-206 to enhance the radiosensitivity of NSCLC cells. PTMA is a target of miR-206 and silencing CYTOR inhibited PTMA expression via miR-206, thus promoting radiosensitivity of NSCLC cells. CYTOR knockdown also enhanced NSCLC cell radiosensitivity in vivo . CYTOR was highly expressed in NSCLC, while silencing CYTOR potentiated NSCLC cell radiosensitivity by upregulating miR-206 and suppressing PTMA. The present study preliminarily revealed the role of CYTOR in radiotherapy sensitivity of NSCLC and provided a novel potential target for the clinical treatment of NSCLC.

show abstract

Section: Discussionsupporting

confidence: 93%

lncRNA cytoskeleton regulator reduces non‑small cell lung cancer radiosensitivity by downregulating miRNA‑206 and activating prothymosin α

Jiang

Yu²,

et al. 2021

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…In addition to sex chromosome-encoded genes, several autosomal genes were up-regulated in adenomas from male patients; of note, PDLIM2, PENK, SOX4, FH, PTMA and TMEM97 are all associated with tumourigenesis [64][65][66][67][68][69], and thus could play a role in the less favourable course of corticotrope adenomas in male patients. Links between these factors and the pituitary are known for PTMA and SOX4, as PTMA nuclear staining has been linked to pituitary tumour size [70], and SOX4 is involved in pituitary development, as shown in both zebrafish [71] and human tissues [72]. Along the same line, another gene overexpressed in male-derived adenomas associated with the pituitary is SPP1 (osteopontin) with increased expression reported in ACTH-secreting adenomas compared to non tumourous pituitary tissue [73] and in corticotrope and lactotrope adenomas compared to other pituitary tumours [49].…”

Section: Discussionmentioning

confidence: 99%

Sexual Dimorphism in Cellular and Molecular Features in Human ACTH-Secreting Pituitary Adenomas

Giraldi

Cassarino

Sesta

et al. 2020

Cancers

View full text Add to dashboard Cite

(1) Background. Cushing’s disease presents gender disparities in prevalence and clinical course. Little is known, however, about sexual dimorphism at the level of the corticotrope adenoma itself. The aim of the present study was to evaluate molecular features of ACTH-secreting pituitary adenomas collected from female and male patients with Cushing’s disease. (2) Methods. We analyzed 153 ACTH-secreting adenomas collected from 31 men and 122 women. Adenomas were established in culture and ACTH synthesis and secretion assessed in basal conditions as well as during incubation with CRH or dexamethasone. Concurrently, microarray analysis was performed on formalin-fixed specimens and differences in the expression profiles between specimens from male and female patients identified. (3) Results. ACTH medium concentrations in adenomas obtained from male patients were significantly lower than those observed in adenomas from female patients. This could be observed for baseline as well as modulated secretion. Analysis of corticotrope transcriptomes revealed considerable similarities with few, selected differences in functional annotations. Differentially expressed genes comprised genes with known sexual dimorphism, genes involved in tumour development and genes relevant to pituitary pathophysiology. (4) Conclusions. Our study shows for the first time that human corticotrope adenomas present sexual dimorphism and underlines the need for a gender-dependent analysis of these tumours. Differentially expressed genes may represent the basis for gender-tailored target therapy.

show abstract

“…In addition, association with age and female sex were found though there was no significant relationship with tumor regrowth [ 118 ]. However, other studies have found no relationship between PTTG expression and invasiveness in PitNETs [ 119 ] or nfPitNETs specifically [ 99 ].…”

Section: Biomarkersmentioning

confidence: 99%

Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors

Whyte,

Nezu,

Chik

et al. 2023

Endocrinol Metab

View full text Add to dashboard Cite

Pituitary neuroendocrine tumors (PitNETs) are the third most frequently diagnosed intracranial tumors, with nonfunctioning PitNETs (nfPitNETs) accounting for 30% of all pituitary tumors and representing the most common type of macroPitNETs. NfPitNETs are usually benign tumors with no evidence of hormone oversecretion except for hyperprolactinemia secondary to pituitary stalk compression. Due to this, they do not typically present with clinical syndromes like acromegaly, Cushing’s disease or hyperthyroidism and instead are identified incidentally on imaging or from symptoms of mass effects (headache, vision changes, apoplexy). With the lack of effective medical interventions, first-line treatment is transsphenoidal surgical resection, however, nfPitNETs often have supra- or parasellar extension, and total resection of the tumor is often not possible, resulting in residual tumor regrowth or reoccurrence. While functional PitNETs can be easily followed for recurrence using hormonal biomarkers, there is no similar parameter to predict recurrence in nfPitNETs, hence delaying early recognition and timely management. Therefore, there is a need to identify prognostic biomarkers that can be used for patient surveillance and as therapeutic targets. This review focuses on summarizing the current evidence on nfPitNETs, with a special focus on potential new biomarkers and therapeutics.

show abstract

Prothymosin-alpha and Ki-67 expression in pituitary adenomas

Abstract: The positive nuclear expression of Ki-67 and PTMA was observed in the majority of pituitary adenomas. Neither the expression of Ki-67 nor that of PTMA-c was related to tumor recurrence or local invasion.

Cited by 6 publications

References 0 publications

lncRNA cytoskeleton regulator reduces non‑small cell lung cancer radiosensitivity by downregulating miRNA‑206 and activating prothymosin α

lncRNA cytoskeleton regulator reduces non‑small cell lung cancer radiosensitivity by downregulating miRNA‑206 and activating prothymosin α

Sexual Dimorphism in Cellular and Molecular Features in Human ACTH-Secreting Pituitary Adenomas

Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors

Contact Info

Product

Resources

About